Novavax (NVAX) Total Non-Current Liabilities (2016 - 2025)
Novavax (NVAX) has 16 years of Total Non-Current Liabilities data on record, last reported at $1.1 billion in Q4 2025.
- For Q4 2025, Total Non-Current Liabilities fell 41.62% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 41.62%, while the annual FY2025 figure was $1.1 billion, 41.62% down from the prior year.
- Total Non-Current Liabilities reached $1.1 billion in Q4 2025 per NVAX's latest filing, down from $1.1 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $3.0 billion in Q2 2022 and bottomed at $1.0 billion in Q2 2025.
- Average Total Non-Current Liabilities over 5 years is $2.1 billion, with a median of $2.0 billion recorded in 2021.
- Peak YoY movement for Total Non-Current Liabilities: surged 351.93% in 2021, then plummeted 47.19% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $2.9 billion in 2021, then fell by 1.71% to $2.8 billion in 2022, then dropped by 12.54% to $2.5 billion in 2023, then decreased by 26.46% to $1.8 billion in 2024, then plummeted by 41.62% to $1.1 billion in 2025.
- Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.